The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2022 | Current status of alloHSCT in BP-MPNs
Guillermo Ortí, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, talks on the current status of allogeneic hematopoietic stem cell transplantation (alloHSCT) in blast phase myeloproliferative neoplasms (BP-MPNs). Dr Ortí explains that patients with BP-MPNs are usually older, and are often not transplant-eligible. Nevertheless, a minority of patients who are transplant-eligible are able to achieve long-term overall survival (OS) and progression-free survival (PFS). In the future, it will be important to determine which patients derive the most benefit from alloHSCT. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
